Coverage
-
April 02, 2026
A Massachusetts federal judge Thursday granted initial approval to a $35 million deal that Teva Pharmaceuticals agreed to pay to resolve claims from a coalition of union healthcare funds that say the company schemed to delay generic competition for its QVAR asthma inhalers.
6 other articles on this case.
View all »